A Phase II Safety and Efficacy Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients With Metastatic Urothelial Cancer

Vascular endothelial growth factor (VEGF) is expressed in human bladder tumors. A phase II study was conducted to assess the VEGF inhibitor pazopanib in patients with metastatic, urothelial carcinoma. Nineteen patients with one prior systemic therapy were enrolled. No objective responses were observ...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Pili, Roberto, Qin, Rui, Flynn, P.J., Picus, Joel, Millward, Michael, Ho, Wing Ming, Pitot, Henry, Tan, Winston, Miles, Kiersten M., Erlichman, Charles, Vaishampayan, Ulka
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4102930/
https://ncbi.nlm.nih.gov/pubmed/23891158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2013.05.005
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki